Next Article in Journal
Challenges for a Sustainable Financial Foundation for Antimicrobial Stewardship
Previous Article in Journal
The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence
 
 
Infectious Disease Reports is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development

by
Ursula Theuretzbacher
1,*,
Christine Årdal
2 and
Stephan Harbarth
3
1
Center for Anti-Infective Agents, Vienna, Austria
2
Norwegian Institute of Public Health, Oslo, Norway
3
Infection Control Program and Division ofInfectious Diseases, University of Geneva Hospitals and Medical Faculty, Geneva, Switzerland
*
Author to whom correspondence should be addressed.
Infect. Dis. Rep. 2017, 9(1), 6836; https://doi.org/10.4081/idr.2017.6836
Submission received: 12 August 2016 / Revised: 12 August 2016 / Accepted: 13 January 2017 / Published: 30 March 2017

Abstract

There is now global recognition that antibiotic resistance is an emerging public health threat. Policy initiatives are underway to provide concrete suggestions for overcoming important obstacles in the fight against antibiotic resistance, like the alarming current paucity of antibacterial innovation. New economic models are needed as incentives for the discovery and development of novel antibacterial therapies especially for infections with too few patients today to justify private sector research and development (R&D) investments. These economic models should focus on rewarding the innovation, not the consumption of the antibiotic since sustainable use policies will reduce selection pressure and slow the emergence of resistance. To effectively stimulate greater innovation, the size of the reward must be commensurate with revenues from other therapeutic areas, estimated at about a billion dollar total pay-out. Otherwise R&D investment will continue to move away from antibiotics to areas where returns are more attractive. A potential sizeable public investment, if implemented, must be protected to ensure that the resulting antibiotics have a lengthy and positive impact on human health. Therefore, public investments in innovation should be bound to sustainable use policies, i.e., policies targeted at a range of actors to ensure the preservation of the novel antibiotics. These policies would be targeted not only at the innovating pharmaceutical companies in exchange for the reward payments, but also at governments in countries which receive the novel antibiotics at reasonable prices due to the reward payment. This article provides some suggestions of sustainable use policies in order to initiate the discussions. These are built on planned policies in the US, EU, WHO and have been expanded to address One Health and environmental aspects to form One World approaches. While further discussion and analyses are needed, it is likely that strong sustainable use policies will help to protect the sizeable public health investments.
Keywords: antibiotics; sustainable use; stewardship; economic incentives antibiotics; sustainable use; stewardship; economic incentives

Share and Cite

MDPI and ACS Style

Theuretzbacher, U.; Årdal, C.; Harbarth, S. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infect. Dis. Rep. 2017, 9, 6836. https://doi.org/10.4081/idr.2017.6836

AMA Style

Theuretzbacher U, Årdal C, Harbarth S. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infectious Disease Reports. 2017; 9(1):6836. https://doi.org/10.4081/idr.2017.6836

Chicago/Turabian Style

Theuretzbacher, Ursula, Christine Årdal, and Stephan Harbarth. 2017. "Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development" Infectious Disease Reports 9, no. 1: 6836. https://doi.org/10.4081/idr.2017.6836

APA Style

Theuretzbacher, U., Årdal, C., & Harbarth, S. (2017). Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infectious Disease Reports, 9(1), 6836. https://doi.org/10.4081/idr.2017.6836

Article Metrics

Back to TopTop